Talk:Vortioxetine

Graph
The graph shows two series for the 20mg dose; this must be a mistake. Does it combine data from two studies? Which data is correct, or from which study?

Second, suggest adding confidence intervals or bands if available. Davidswelt (talk) 12:50, 30 October 2023 (UTC)

Scope
WPMED generally does not include individual investigational molecules within its scope. WhatamIdoing (talk) 21:59, 8 February 2010 (UTC)

WP:PHARM rating
Demoted to Start: no interactions, no contraindications and very little on side effects. --ἀνυπόδητος (talk) 19:28, 8 October 2013 (UTC)

Accepted by the EMA for europe
Five days ago, the vortioxetine was approved by the EMA for the treatment of MDD in europe: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002717/smops/Positive/human_smop_000601.jsp&mid=WC0b01ac058001d127

I have no idea how to edit the aritcle ;) — Preceding unsigned comment added by 37.80.114.27 (talk) 14:14, 30 October 2013 (UTC)

Pharmacokinetics?
What kind of article is this? Can someone please fix that crap? — Preceding unsigned comment added by 186.206.200.219 (talk) 00:54, 15 March 2014 (UTC)

proposed changes
·Information to be added:

Suicide/suicidal thoughts or clinical worsening Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical studies of antidepressants in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo, in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany treatment especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted to the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.

·Explanation of issue: At the top of the page, there is a mention to serious side effects related to suicide ("Serious side effects may include suicide in those under the age of 25"). This mention is a section of the SmPC and miss essential information related to Suicide/suicidal thoughts clinical worsening. It is important to include the full class label related to the SmPC as stated above with the below reference.

·References supporting change: https://www.medicines.ie/medicines/brintellix-10-mg-film-coated-tablets-34817/patient-info

AudreyDufour (talk) 10:10, 5 February 2020 (UTC)

Reply 5-FEB-2020
Regards, Spintendo  20:23, 5 February 2020 (UTC)
 * Wikipedia is WP:NOT a package insert, and thus this expanded information from the product's PI is not necessary here in full. Several links to monographs and such are already included elsewhere in the article, such that expanding the text through this edit request allows no more information than what is already provided for the reader to access, if desired.

Too
Hola 190.237.25.110 (talk) 21:30, 26 June 2022 (UTC)